Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia

NCT ID: NCT05660135

Last Updated: 2025-08-24

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 4000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-06-20
• Study Completion Date: 2025-12-31

Brief Summary

This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive patients with dyslipidemia.

Detailed Description

In this study, investigator will evaluate subjects' clinical performance in actual care. Laboratory test results such as demographic information and medical treatment, blood pressure, blood lipid test, and liver function test conducted at the start date of Olomax tablet administration and subsequent 24 weeks (± 8 weeks) will be collected. In the case of safety-related information, such as abnormal cases, data shall be collected at any time during the 24-week follow-up period if there is a visit by the study subject according to daily treatment.

Conditions

Hypertension; Dyslipidemias

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

patients with hypertension and dislipidemia

received olomax tablet as treatment.

Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca

Intervention Type: DRUG

Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg

Interventions

Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca

Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Adult aged 19 or older at the time of the baseline visit.

2. A patient with hypertension and dyslipidemia who is scheduled to administer olomax tablet according to investigator's medical judgement.

• Patients who were previously taking more than two tablets of a single drug, low-density lipoprotein-cholesterol (LDL-C)
• Patients who were previously only taking blood pressure-lowering drugs and did not take LDL-C-lowering drugs, but who need to take additional LDL-C-lowering drugs at the discretion of the researcher
• Patients who were previously taking LDL-C lowering agents and did not take blood pressure lowering agents, but who need to take additional blood pressure lowering agents according to the researcher's judgment
• Patients who have not previously taken both a blood pressure drop and an LDL-C drop but need additional simultaneous use at the discretion of the researcher

3. A person who can understand the information provided to him/her and may voluntarily sign a written consent form

Exclusion Criteria

1. A person who falls under the prohibition of administration according to the permission for olomax tablet

2. A person who has a history of administering olomax tablets before participating in this study

3. In addition to the above, a person that the investigator thinks he/she is not suitable for participating in this observation study;

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hun-Sung Kim

Role: PRINCIPAL_INVESTIGATOR

The Catholic University of Korea

Locations

The Catholic University of Korea, Seoul ST. Mary's Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

DWOLM_RWE02

Identifier Type: -

Identifier Source: org_study_id